Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy

The evidence for DPP-4 inhibitors effectiveness at the late stages of type 2 diabetes mellitus (T2DM) are still growing. This is particularly important for those patients who receive insulin without adequately glycemic control. This publication provides the overview of studies which demonstrate high...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gagik Radikovich Galstyan, Svetlana Viktorovna Sergeeva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	dipeptidyl peptidase-4 inhibitors diabetes mellitus 2 type insulin therapy vildagliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/d475d6cca7794363a7a0ff5051ec970b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d475d6cca7794363a7a0ff5051ec970b
record_format	dspace
spelling	oai:doaj.org-article:d475d6cca7794363a7a0ff5051ec970b2021-11-14T09:00:20ZPossible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy2072-03512072-037810.14341/DM7624https://doaj.org/article/d475d6cca7794363a7a0ff5051ec970b2015-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7624https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The evidence for DPP-4 inhibitors effectiveness at the late stages of type 2 diabetes mellitus (T2DM) are still growing. This is particularly important for those patients who receive insulin without adequately glycemic control. This publication provides the overview of studies which demonstrate high efficacy of Vildagliptin in reducing the blood glucose level in patients with hight duration of T2DM and insulin therapy. DPP-4 inhibitors normalize basal and postprandial glucagon secretion with pancreas α-cells that helps to provide better glycemic control and to reduce a risk of hypoglycemia. Besides, there are very interesting data for Vildagliptin to reduce insulin requirement in T2DM patients in addition to HbA1clevel decrease.Gagik Radikovich GalstyanSvetlana Viktorovna SergeevaEndocrinology Research Centrearticledipeptidyl peptidase-4 inhibitorsdiabetes mellitus 2 typeinsulin therapyvildagliptinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 4, Pp 87-91 (2015)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	dipeptidyl peptidase-4 inhibitors diabetes mellitus 2 type insulin therapy vildagliptin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	dipeptidyl peptidase-4 inhibitors diabetes mellitus 2 type insulin therapy vildagliptin Nutritional diseases. Deficiency diseases RC620-627 Gagik Radikovich Galstyan Svetlana Viktorovna Sergeeva Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
description	The evidence for DPP-4 inhibitors effectiveness at the late stages of type 2 diabetes mellitus (T2DM) are still growing. This is particularly important for those patients who receive insulin without adequately glycemic control. This publication provides the overview of studies which demonstrate high efficacy of Vildagliptin in reducing the blood glucose level in patients with hight duration of T2DM and insulin therapy. DPP-4 inhibitors normalize basal and postprandial glucagon secretion with pancreas α-cells that helps to provide better glycemic control and to reduce a risk of hypoglycemia. Besides, there are very interesting data for Vildagliptin to reduce insulin requirement in T2DM patients in addition to HbA1clevel decrease.
format	article
author	Gagik Radikovich Galstyan Svetlana Viktorovna Sergeeva
author_facet	Gagik Radikovich Galstyan Svetlana Viktorovna Sergeeva
author_sort	Gagik Radikovich Galstyan
title	Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
title_short	Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
title_full	Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
title_fullStr	Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
title_full_unstemmed	Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
title_sort	possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
publisher	Endocrinology Research Centre
publishDate	2015
url	https://doaj.org/article/d475d6cca7794363a7a0ff5051ec970b
work_keys_str_mv	AT gagikradikovichgalstyan possibleapplicationsofgliptinsdipeptidylpeptidase4inhibitorsinpatientswithtype2diabetesmellitusonthevariousmodesofinsulintherapy AT svetlanaviktorovnasergeeva possibleapplicationsofgliptinsdipeptidylpeptidase4inhibitorsinpatientswithtype2diabetesmellitusonthevariousmodesofinsulintherapy
_version_	1718429557634105344

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy

Ejemplares similares